Table 5 Summary of studies detecting IgG anti-IgE antibodies in subjects with CSU and healthy controls
Reference (author, year) | Region | Definition of CSU in weeks | Number of CSU patients undergoing testing | Number of healthy controls undergoing testing | % prevalence of IgG anti-IgE autoantibody in study group | Functional assay (F) or non-functional assay (N) | % prevalence of IgG anti-IgE autoantibody in control group | Number of antihistamine (AH) and/or systemic corticosteroid (SC)-free days |
|---|---|---|---|---|---|---|---|---|
Gruber, 1988 [100] | United States | – | 6 | 32 | 50 | N | 0 | Not stated |
Fiebiger, 1995 [11] | Austria | > 8 | 32 | 15 | 69 | N | 26 | Not stated |
Tong, 1997 [101] | United States | > 12 | 50 | 20 | 12 | F | 5 | 2 (AH) |
Eckman, 2008 [94] | United States | > 6 | 73 | 23 | 45 | N | 30 | Not stated |
Rojanapremsuk, 2015 [102] | United States | > 6 | 438 | – | 33 | N | – | Not stated |